SeaStar Medical Reports Quadrupled Sales for QUELIMMUNE, Expands Focus to Adult Acute Kidney Injury Market
TL;DR
SeaStar Medical's QUELIMMUNE sales saw a fourfold increase, driving revenue growth and potential market dominance in critical care treatments.
QUELIMMUNE, SeaStar Medical's FDA-approved product, connects to existing hemodialysis systems, offering organ-sparing and cost-effective treatment for pediatric AKI patients.
SeaStar Medical's innovative therapies aim to save lives by providing potential life-saving treatments for critically ill pediatric patients, with plans to expand to adult AKI market.
SeaStar Medical's rapid revenue growth and expansion plans in critical care treatments showcase a promising future for patients and healthcare advancements.
Found this article helpful?
Share it with your network and spread the knowledge!
Medical device company SeaStar Medical reported a fourfold increase in first-quarter sales for QUELIMMUNE, its FDA-approved treatment for pediatric acute kidney injury (AKI), signaling potential market expansion and strategic growth.
The company's QUELIMMUNE product, currently approved for pediatric patients with AKI due to sepsis, saw net product revenue increase to $293,000 in the first quarter of 2025, compared to $67,500 in the previous quarter. This growth reflects increasing adoption among pediatric healthcare providers and demonstrates the therapy's potential clinical value.
SeaStar is now targeting the significantly larger adult AKI market, which represents an estimated $4.5 billion annual opportunity. The company's NEUTRALIZE-AKI pivotal trial, focused on adult patients, has reached 50% enrollment and is expected to support a potential FDA approval in 2026.
CEO Eric Schlorff emphasized the company's commitment to expanding its therapeutic reach, noting that QUELIMMUNE offers organ-sparing and potentially life-saving outcomes for critically ill patients. The therapy's ability to integrate with existing hospital workflows provides a strategic advantage in market penetration.
The company's financial performance also showed improvement, with net losses narrowing to $3.8 million in the first quarter, compared to $12.7 million in the same period last year. SeaStar concluded the quarter with $5.3 million in cash, supported by a $6 million registered direct offering.
As SeaStar continues to advance its Selective Cytopheretic Device (SCD) therapy, the company is positioning itself as an innovative player in treating critical care patients with organ failure risks, with particular focus on expanding treatment options for both pediatric and adult populations.
Curated from NewMediaWire
